|
1) Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-76
|
|
|
|
2) Spitzer WO. Quality of life and functional status as target variables for research. In: Guggenmoos-Holzmann I, et al. editors. Quality of Life and Health, concepts, methods applications. Berlin: Blackwell Wissenschafts-Verlag; 1995. p.59-67
|
|
|
|
|
|
3) Hui C, Triandis HC. Measurement in cross-cultural psychology: a review and comparison of strategies. Cross Cultural Psychol. 1985; 16: 131-52
|
|
|
|
|
|
4) Kobayashi K, Takeda F, Teramukai S, et al. A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer. 1998; 34: 810-5
|
|
|
|
|
|
5) Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-9
|
|
|
|
|
|
6) Fumimoto H, Kobayashi K, Chang CH, et al. Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res. 2001; 10: 701-9
|
|
|
|
|
|
7) Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-83
|
|
|
|
|
|
8) Fukuhara S, Ware JE Jr, Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol. 1998; 51: 1045-53
|
|
|
|
|
|
9) Kurihara M, Shimizu H, Tsuboi K, et al. The development of quality of life questionnaire in Japan: Quality of life assessment of patients receiving chemotherapy. Psycho-Oncology. 1999; 8: 355-63
|
|
|
|
|
|
10) Kobayashi K, Green J, Shimonagayoshi M, et al. Validation of the Care Notebook for measuring physical, mental and “life well-being" of patients with cancer. Quality of Life Research 2005; 14: 1035-43
|
|
|
|
|
|
11) Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994; 30A(5): 635-42
|
|
|
|
|
|
12) Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995; 12: 199-220
|
|
|
|
|
|
13) Saitoh E, Yokomizo Y, Chang CH, et al. Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung. J Nippon Med Sch. 2007; 74: 402-8
|
|
|
|
|
14) Fairclough DL, Peterson HF, Cella D, et al. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med. 1998; 17: 781-96
|
|
|
|
|
|
15) Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16: 139-44
|
|
|
|
|
|
16) Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire？ Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002; 55: 285-95
|
|
|
|
|
|
17) Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2006; 24: 3831-7
|
|
|
|
|
|
18) Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-8
|
|
|
|
|
|
19) Yoshizawa H, Kobayashi K, Inoue A, et al. QOL analysis from NEJ 002 study comparing gefitinib to chemotherapy for non-small cell lung cancer with mutated EGFR. ESMO 2010 (proceeding)
|
|
|
|
|
|
20) Groenvold M, Petersen MA, Aaronson NK, et al. EORTC Quality of Life Group. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006; 42: 55-64
|
|
|
|
|
|
21) Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004; 22: 714-24
|
|
|
|
|
|
22) Mills ME, Murray LJ, Johnston BT, et al. Does a patient-held quality-of-life diary benefit patients with inoperable lung cancer？ J Clin Oncol. 2009; 27: 70-7
|
|
|
|
|